Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents (SWITCHCore)

This study has been completed.
Information provided by (Responsible Party):
Sunovion Identifier:
First received: June 10, 2010
Last updated: April 9, 2013
Last verified: April 2013
Results First Received: May 15, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Schizophrenia
Schizoaffective Disorder
Intervention: Drug: Lurasidone HCl

  Participant Flow

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Lurasidone Open-Label Arm 40/40 Lurasidone 40 mg orally once daily for 14 days followed by 4 weeks of flexible dosing 40-120mg
Lurasidone Open-Label Arm 40/80 Lurasidone 40mg for 7 days, followed by Lurasidone 80 mg for 7 days, orally once daily, followed by 4 weeks of flexible dosing 40-120mg once daily
Lurasidone Open-Label Arm 80/80 Lurasidone 80 mg once daily orally for two weeks, followed by Lurasidone 40-120mg once daily for 4 weeks
Total Total of all reporting groups

Baseline Measures
    Lurasidone Open-Label Arm 40/40     Lurasidone Open-Label Arm 40/80     Lurasidone Open-Label Arm 80/80     Total  
Number of Participants  
[units: participants]
  72     87     81     240  
Age [1]
[units: participants]
<=18 years     1     1     0     2  
Between 18 and 65 years     71     85     81     237  
>=65 years     0     1     0     1  
Age [1]
[units: years]
Mean (Standard Deviation)
  43.2  (11.3)     44.0  (11.5)     44.4  (10.0)     43.9  (10.9)  
Gender [1]
[units: participants]
Female     25     37     22     84  
Male     47     50     59     156  
Region of Enrollment [1]
[units: participants]
United States     72     87     81     240  
[1] 244 patients were randomized, 240 received study medication.

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Time to Relapse of Psychotic Symptoms During 6 Weeks   [ Time Frame: 6 Weeks ]

2.  Secondary:   Tolerability and Safety   [ Time Frame: 6 Weeks ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information